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Abstract
DKA is a severe metabolic derangement characterized by dehydration, loss of electrolytes, hyperglycemia, hyper-
ketonemia, acidosis and progressive loss of consciousness that results from severe insulin deficiency combined with
the effects of increased levels of counterregulatory hormones (catecholamines, glucagon, cortisol, growth hor-
mone). The biochemical criteria for diagnosis are: blood glucose > 200 mg/dl, venous pH <7.3 or bicarbonate <15
mEq/L, ketonemia >3 mmol/L and presence of ketonuria. A patient with DKA must be managed in an emergency
ward by an experienced staff or in an intensive care unit (ICU), in order to provide an intensive monitoring of the
vital and neurological signs, and of the patient’s clinical and biochemical response to treatment. DKA treatment
guidelines include: restoration of circulating volume and electrolyte replacement; correction of insulin deficiency
aiming at the resolution of metabolic acidosis and ketosis; reduction of risk of cerebral edema; avoidance of other
complications of therapy (hypoglycemia, hypokalemia, hyperkalemia, hyperchloremic acidosis); identification and
treatment of precipitating events. In Brazil, there are few pediatric ICU beds in public hospitals, so an alternative
protocol was designed to abbreviate the time on intravenous infusion lines in order to facilitate DKA management
in general emergency wards. The main differences between this protocol and the international guidelines are:
intravenous fluid will be stopped when oral fluids are well tolerated and total deficit will be replaced orally; if
potassium analysis still indicate need for replacement, it will be given orally; subcutaneous rapid-acting insulin ana-
log is administered at 0.15 U/kg dose every 2-3 hours until resolution of metabolic acidosis; approximately
12 hours after treatment initiation, intermediate-acting (NPH) insulin is initiated at the dose of 0.6-1 U/kg/day, and
it will be lowered to 0.4-0.7 U/kg/day at discharge from hospital.
Introduction
Diabetic ketoacidosis (DKA) is an acute and life-threa-
tening complication of diabetes mellitus (DM) and con-
sists of the biochemical triad of hyperglycemia,
ketonemia, and metabolic acidosis [1]. Even in reference
centers, 15 to 67% of diabetic patients still present DKA
as the first manifestation of type 1 diabetes, mainly in
children under 5 years old and in populations with diffi-
cult access to health services for socioeconomic reasons
[2,3]. In Brazil, recent studies have shown that DKA was
present in 32,8 to 41% of the patients at the time of
diagnosis of type 1 DM [4-7], in agreement with inter-
national data. DKA is the most frequent cause of hospi-
talization and mortality among type 1 diabetes children
and adolescents, and it accounts for approximately 50%
of all deaths of DM individuals up to 24 years of age
[8]. However, type 2 DM patients are also susceptible to
DKA under stressful situations such as infections, sur-
gery or trauma [9]. In developed countries, DKA mortal-
ity rate is 0.15% to 5% [10,11] and it is mainly due to
cerebral edema, occurring in about 1% of the cases [2];
epidemiological data on DKA morbidity and mortality
are still scarce in Brazil. An accurate diagnosis and care-
ful management of the situation are crucial to reduce
the related complications. In our country, there are few
pediatric intensive care unit (ICU) beds in public hospi-
tals, which are usually occupied by children who
demand ventilatory support; therefore most of DKA
patients will be managed in general emergency wards.
We report here a local experience with an alternative
fluid and insulin therapy protocol designed to abbreviate
the time on intravenous infusion line for the manage-
ment of uncomplicated DKA cases in a Brazilian pedia-
tric emergency department. * Correspondence: thais.manna@icr.usp.br
1Pediatric Endocrine Unit, Instituto da Criança do Hospital das Clínicas da
Faculdade de Medicina da Universidade de São Paulo, Brazil
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DKA is the consequence of a complex disturbance in
carbohydrate, protein and lipid metabolism, due to rela-
tive or absolute insulin deficiency and elevated counter-
regulatory hormone (glucagon, catecholamines, cortisol
and growth hormone) levels [1,12], causing accelerated
catabolism with increased glucose production by the
liver (via glycogenolysis and glyconeogenesis) and
decreased peripheral glucose uptake, which creates
progressive hyperglycemia.
Blood glucose levels higher than 180 mg/dl usually
surpass renal glucose absorption threshold, leading to
glycosuria and osmotic diuresis, which causes water and
electrolytes (sodium, potassium, phosphorus and magne-
sium) losses, determining a severe depletion in intravas-
cular volume that may impair kidney perfusion and
further compromise the renal ability to excrete glucose
worsening hyperglycemia [1,2], and consequently the
serum hyperosmolality [13]. However, in DKA the clini-
cal assessment of dehydration is easily underestimated,
as such clinical signs are determined mainly by the
extracellular volume, which is maintained by
hyperosmolality.
Extreme insulinopenia associated with accelerated cat-
abolism generates a high degree of lipolysis and a conse-
quent increase in hepatic oxidation of free fatty acids
into ketone bodies (beta-hidroxybutirate and acetoace-
tate), which are highly responsible for DKA metabolic
acidosis [12,14]. Also, the hypovolemia that results from
osmotic diuresis and vomiting decreases peripheral per-
fusion, leading to the accumulation of lactic acid in the
tissues, which contributes to metabolic acidosis on a
lower degree. Generally, acetoacetate is converted into
acetone, which is eliminated by urine and by breathing;
however, lactic acidemia present in DKA increases acet-
oacetate conversion into beta-hidroxybutirate, which
impairs the renal ability to excrete such ketoacids,
characterizing DKA as an increased anion gap metabolic
acidosis [15] (Table 1).
Hypertonicity provokes an osmotic flux of water from
the intracellular to the extracellular compartment and
nearly all body cells (except for neurones) go through
an intracellular dehydration process. This water trans-
cellular shift also generates an extracellular efflux of
potassium, further aggravated by metabolic acidosis,
causing a high intracellular potassium deficit [12,15,16].
The total-body potassium deficit occurs mainly due to
vomiting and osmotic diuresis; however, despite the
total depletion, serum potassium levels at diagnosis may
be increased, normal or decreased [12,15].
Hyperglycemia is the determining factor of serum
hyperosmolality, responsib l ef o rt h eo s m o t i cf l u xo f
water to extracellular space, which may cause dilutional
hyponatremia; it is estimated that for each 100 mg/dl
blood glucose concentration above the limit of 100 mg/
dl, there is a 1.6 mEq/L reduction in serum sodium. In
general, there is also a depletion of total-body phosphate
related to osmotic diuresis too, and an accentuated fall
in its serum levels is observed after starting insulin
replacement, which provokes a rapid intracellular shift
of phosphate [12,17].
Dehydration, hyperosmolality, acidosis and electrolytic
disorders lead to the release of counterregulatory
hormones, perpetuating the decompensation cycle [18]
(Figure 1).
In severe cases of DKA, hyperpnea may cause a very
low pCO2 and, consequently, there will be a decreased
CO2 diffusion through the hematoencephalic barrier
determining a low pCO2 in the smooth muscles of cere-
bral vessels and an increased extracellular fluid pH,
which can provoke cerebral vasoconstriction [19]. The
biochemical criteria for DKA definition and categoriza-
tion can be found in Table 1[12,16].
Intercurrent illnesses in addition to intense physical or
emotional stress are risk factors for DKA; however, diffi-
culties in coping with insulin and diet therapies, peripu-
bertal emotional instability, poor metabolic control, lack
of family support, psychiatry disorders, limited access to
medical services, insulin pump failure, use of drugs with
hyperglycemiant effect may increase the risk for DKA
[5,14,16].
The leading clinical manifestation is dehydration,
which may be mild, moderate or severe with hemo-
dynamic instability (capillary refill time > 3 seconds,
weak pulses, cool extremities, tachycardia, normal or
lower blood pressure) and despite dehydration, with only
a few exceptions, urine output is considerable. Intense
ketogenesis causes a rampant clinical condition, with
nausea, vomiting, abdominal pain, hyperpnea (from mild
to Kussmaul breathing), facial redness and ketotic breath.
Initial assessment of the DKA patient must include
detailed physical examination, focusing on the circu-
latory state (pulse, blood pressure and peripheral
Table 1 Biochemical criteria for DKA definition and
categorization [12,16]
DKA
mild moderate severe
Blood glucose (mg/dl) > 200 >200 >200
Serum pH < 7.3 < 7.2 < 7.1
Serum bicarbonate (mEq/L) <1 5 <1 0 <5
Ketonemia (mmol/L) >3 >3 >3
Ketonuria present present present
Serum osmolality (mOsm/kg) variable variable variable
Anion gap (normal = 12 ± 2 mEq/L) > 12 >12 >12
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Page 2 of 9perfusion), dehydration degree, level of consciousness,
presence of acidotic breathing, ketotic breath, or signs
of associated infectious conditions. Finger-stick capillary
blood glucose and ketonemia testing must be conducted
at the bedside, ketonuria and glycosuria shall be moni-
tored using urine reactive strips. Biochemical assessment
will include venous blood glucose, blood gases, serum
electrolytes (sodium, potassium, chloride, phosphorus),
urea and creatinine, allowing for the calculation of
serum osmolality and anion gap [12,20] (formulas in
Table 2).
In severely obtunded, unconscious patients or with
signs of respiratory failure, orotracheal intubation and
nasogastric tube should be placed in order to establish a
safe air flow [12,21]. In this situation, it is recommended
to preserve “adaptive tachypnea” for the acidosis level
[22,23], in order to avoid exaggerated vasoconstriction
due to an accentuated drop in pCO2 levels, or otherwise
increased vasodilatation secondary to the excessively
increased pCO2 levels.
Moderate-to-severe dehydrated patients should be man-
aged in a medical center specialized in critical care, where
they can be constantly monitored and reassessed [14,20].
DKA treatment aims to correct dehydration, electro-
lytic disorders, hyperglycemia and acid-base imbalance,
as well as identifying and controlling the triggering fac-
tors in order to avoid the complications resulting from
such procedures [12,14,20].
Replacement of body fluids is important for repair of
circulation and renal functions, enhancing glucose
excretion and decreasing levels of counterregulatory
hormones that stimulate hyperglycemia [24].
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Figure 1 Pathophysiology of diabetic ketoacidosis (DKA) and of hyperglycemic hyperosmolar state (HHS) (modified from [16]).
Table 2 Formulas used to calculate serum osmolality and anion gap in DKA [12]
Effective osmolality (normal = 280-290 mOsm/kg) = 2 × [Na
+ +K
+] + glucose (mg/dl)/18
Anion gap (normal = 12 ± 2 mEq/L) =N a
+ (mEq/L) - [Cl
- +HCO3
-(mEq/L)]
Savoldelli et al. Diabetology & Metabolic Syndrome 2010, 2:41
http://www.dmsjournal.com/content/2/1/41
Page 3 of 9The objectives of fluid and electrolyte replacement
therapy in DKA are restoration of circulating volume,
replacement of sodium and the extracellular and intra-
cellular fluid deficit of water, restoration of glomerular
filtration with enhanced clearance of glucose and
ketones from the blood, and avoidance of excessive
rates of fluid administration so as not to exacerbate the
risk of cerebral edema [14,20] (Figure 2).
Initial intravenous fluid administration should begin
immediately with an isotonic solution (0.9% sodium
chloride) in a 10 to 20 ml/kg bolus over 1 to 2 hours.
Subsequent fluid management (deficit replacement)
should be with 0.9% normal saline for at least 4-6 hours;
thereafter, deficit replacement should be with a solution
with a tonicity greater than or equal to 0.45% saline
with added potassium [14,20,25]. The remainder repla-
cement intravenous fluid should be given over at least
48 hours. Urinary losses should not be added to the
calculation of replacement fluids [14,20,25].
Potassium replacement may be initiated as soon as
urine output is documented, as long as serum potassium
levels are ≤ 6.5 mEq/L, usually from the second hour of
resuscitation phase, and 20-40 mEq/L of potassium will
be included to the fluid regimen, at a maximum rate of
0.5 mEq/kg/hour [12,14,26]. There is no consensus
about administering potassium chloride or potassium
phosphate, and a total correction with a 19.1% potas-
sium chloride (KCl) solution is also accepted. If potas-
sium phosphate salts are used, it is recommended to use
half of 25% monopotassium phosphate (1 ml = 1.8 mEq
of potassium) and half of 19.1% KCl (1 ml = 2.5 mEq of
potassium) [14,20]
Phosphate levels are usually low in DKA and may
drop even further after insulin therapy is initiated; there
is a theoretical reason for its replacement that is the
decrease in tissue oxygenation due to a fall in 2,3
diphosphoglycerate (2,3 DPG) levels (phosphate deple-
tion syndrome), however, the benefits of its replacement
have not yet been proven, since it may induce hypo-
calcemia and hypomagnesemia [26,27].
Insulin therapy must be initiated 1-2 hours after the
beginning of fluid resuscitation, if there has already been
an improvement in peripheral perfusion; then, low insu-
lin doses may be administered by intravenous (IV),
intramuscular (IM) or subcutaneous (SC) route
[1,18,28,29]. Continuous IV infusion of low doses of
human regular insulin has been chosen most often as it
causes more predictable fall of blood glucose levels, and
i ta l l o w sf o rm o r ei m m e d i a t ed o s ea d j u s t m e n t s
[12,18,20]. Nevertheless, IV insulin administration
requires another venous line to allow independent hand-
ling of fluid hydration and of the insulin infusion rate.
Human regular insulin should be infused at the dose
of 0.1 U/Kg/hour (for instance: 50 U in 500 ml of 0.9%
saline solution, where 1 ml = 0.1 U) aiming to promote
a plasma glucose concentration fall at a rate of 50-
90 mg/dl/hour [12,14,20]. Capillary blood glucose
should be measured hourly, as well as the rate of falling
of plasma glucose concentrations; if the patient demon-
strates marked sensitivity to insulin, 5% glucose shall be
added to the saline solution or insulin dose may be
reduced to 0.05 U/Kg/hour, so that IV insulin therapy
is kept until ketosis and metabolic acidosis are under
control [12,14,20].
In most DKA events, metabolic acidosis control will
occur as a consequence of fluid replacement and insulin
therapy; however, in severe cases when pH < 6.9, alkali
therapy may be indicated in order to prevent decreased
cardiac contractility and peripheral vasodilatation that
could further impair tissue perfusion [20]. Bicarbonate
administration of 1-2 mEq/kg would be done over 1-
2 hours or according to the following formula:
Bicarbonate to be administered (mEq) = (15 - Bicarbo-
nate found) × 0.3 × weight (kg)
Venous blood sampling should be obtained every
2 hours for monitoring plasma glucose, serum electro-
lytes (sodium, potassium, chloride, phosphorus), blood
urea, creatinine levels, and blood gases until metabolic
acidosis is corrected. In case a phosphate solution is
used at rehydration phase, it is also recommended to
monitor calcium and magnesium levels [12,14,26].
When metabolic acidosis is controlled (pH > 7.3,
bicarbonate > 15, and/or anion gap = 12 ± 2) [12,14,20],
IV regular insulin may be replaced by intermittent SC
regular insulin administration (0.1 U/kg every 4 hours),
which must be initiated 1-2 hours before interrupting
the IV regular insulin infusion.
Alternative DKA treatment protocol
Our alternative treatment protocol for uncomplicated
DKA cases was designed to abbreviate the time on
intravenous fluid and insulin replacement in order to
simplify the management of this condition in the gen-
eral pediatric emergency wards. The objectives of this
alternative protocol are: a) restoration of extracellular
fluid volume; b) replacement of sodium and potassium
deficits; c) control of metabolic acidosis and ketonemia;
d) control of hyperglycemia; e) reduction of risk of cere-
bral edema.
In this protocol, fluid replacement is initiated before
insulin therapy, as normalization of peripheral perfusion
is also necessary for insulin to reach the receptors in the
target tissues. The aim of fluid therapy is expanding the
intravascular compartment until peripheral circulation is
normalized; it is initiated with a 0.9% sodium chloride
solution (normal saline) - 20 ml/kg/hour (maximum
1.000 ml/hour) and additional parts of normal saline -
10 to 20 ml/kg/hour will be repeated, if necessary, until
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Page 4 of 9Clinical history 
. polyuria 
. polydipsia 
. weight loss 
. vomiting 
. abdominal pain 
. confusion 
Clinical signs 
. dehydration and/or 
hemodinamic instability 
. deep sighing respiration 
. ketotic breath 
Biochemical investigation 
. ketones in urine or capillary blood 
. blood glucose 
. blood gases and electrolytes 
. investigate infection if indicated 
DKA confirmed 
. Hyperglycemia (blood glucose> 200mg/dl) 
. Venous pH <7.3 or bicarbonate <15
mmol/L 
. Ketonemia and/ or ketonuria. 
Shock  Dehydration >5% 
Acidotic
Vomiting 
Minimal dehydration 
  Oral fluids tolerated 
. Secure Airway ± NG tube 
. Breathing: give O2  
. Circulation: 0.9% saline 
solution 10-20ml/kg over 1-
2h. (repeat until circulation 
restored but not exceeding 
30ml/kg) 
. Calculate fluid requirement 
to be corrected over 48hours 
. 0.9% saline solution
. ECG for abnormal T waves 
. start potassium 
replacement now  only  if 
patient hypokalemic 
. Start SC insulin and oral 
hydration 
. No improvement 
.After initial hydration: 
. Start insulin therapy 
  -Continous IV regular insulin (0.1U/kg/hour)  
. Start potassium replacement IF diuresis present and 
initial K<6.5mEq/L, 20-40 mEq/L of potassium in the 
hydration fluid, at a maximum rate of 0.5 mEq/kg/hour 
. Monitor:
-blood glucose hourly 
-fluids input and output hourly 
-neurologic status at least hourly 
-ketonuria  
-electrolytes and blood gases every 2 hours 
. No improvement 
. Improvement (clinically 
well, tolerating oral fluids) 
Neurologic deterioration 
 (headache, irritability, 
increased drowsiness, urine 
incontinence, specific 
neurological signs and 
slowing heart rate) 
.Add 5% glucose to 0.9% 
saline solution (1:1) when 
blood glucose <200mg/dl
or blood glucose fall  more 
than 100mg/dl/hour 
. Adjust sodium infusiom to 
promote an increase in 
measured serum sodium 
. Reassess:
-fluid replacement 
-insulin dose and infusion 
-consider sepsis 
Transition to SC insulin 
- replace IV regular insulin by intermittent 
subcutaneous regular insulin administration ,  
initiated 1-2 hours before interrupting the IV 
regular insulin infusion 
.Cerebral edema suspition 
(exclude hypoglycemia) 
Start treatment: 
. mannitol 0.5-1g/kg IV, in 20 
minutes, repeated if no response 
within 30 minutes and 2 hours;  
. reduce fluid infusion by 1/3 
. elevate head of the bed  
. move to ICU 
. cranial image AFTER patient 
stabilised
Figure 2 Management of diabetic ketoacidosis (adapted from [20]).
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Page 5 of 9restoration of peripheral perfusion usually after 4-
6 hours; in the presence of shock, 50 ml/kg may be
infused over the first hour (maximum 1.000 mL/hour).
During resuscitation phase, if blood glucose levels reach
200 mg/dl or lower, a 5% glucose solution may be
added to 0.9% saline solution (half and half).
Maintenance fluid (100 ml/100 kcal/day) will be admi-
nistered only if oral fluids could not be tolerated; there-
fore, total fluid deficit will not be replaced by intravenous
fluids. Gradual and continuous oral rehydration will
promote a slower correction of hyperosmolality.
Since 1996, we use in our emergency department an
alternative insulin therapy protocol with SC rapid-acting
analog (lispro or aspart), which was validated by a ran-
domized clinical trial comparing 30 DKA episodes trea-
ted in such protocol with other 30 episodes treated with
continuous intravenous insulin infusion [30]. In this
regard, a recent evidence-based review concluded that
the use of subcutaneously administered rapid-acting
insulin analogs is safe and effective for the management
of uncomplicated DKA [31]. All the 60 DKA episodes
enrolled in our randomized clinical trial received the
same fluid replacement therapy described above.
The biochemical characteristics of both branches of the
study during the first 30 hours of DKA management are
illustrated in Table 3.
According to this alternative insulin therapy protocol,
SC rapid-acting analog is initiated at a dose of 0.15 U/
kg every 2 hours, reducing it to 0.1 U/kg in case the
rate of falling of plasma glucose concentrations exceeds
100 mg/dl/hour, until resolution of metabolic acidosis
[30,32]. In order to avoid hypoglycemia, 5% glucose
solution will be added to saline solution (1:1) when
blood glucose levels are close to 200 mg/dl. Approxi-
mately 12 hours after the treatment beginning, when
metabolic acidosis is usually under control, intermedi-
ate-acting (NPH) insulin is initiated at the dose of 0.6-1
U/kg/day. This higher dose is required to compensate
for the insulin resistance determined by DKA, and it
will be frequently associated with extra SC 0.1 U/kg
doses of rapid-acting analog according to capillary blood
glucose monitoring every 3 hours. NPH insulin dose
will be lowered to 0.4-0.7 U/kg/day at discharge from
hospital.
Oral fluids may be introduced upon improvement of the
level of consciousness, nauseas and vomiting. If oral accep-
tance is not enough to keep blood glucose levels between
90 and 180 mg/dl [33-36], an IV fluid solution with 5%
glucose will be maintained, so that insulin therapy is not
interrupted before the ketogenic process is totally under
control. Oral potassium replacement may be maintained
based on serum potassium measurements [20].
DKA-related complications
Patients must be monitored for possible complications,
such as hypoglycemia, hypokalemia, cardiac arrhythmia,
venous and arterial thrombotic phenomena, and more
rarely pneumomediastinum, pneumopericardium and
subcutaneous emphysema [37,38], however, cerebral
edema is the main cause of DKA-associated mortality
[12,14].
Cerebral edema may occur in 0.5-1% of all DKA cases
in childhood, and usually develops 5-15 hours after
treatment has started, followed by high morbidity rates,
with permanent neurological handicap from 10-25% and
mortality from 20-25% [12]. Risk factors associated with
cerebral edema would be: age inferior to 5, recent DM
diagnosis, long-standing symptoms, hypocapnia, severe
acidosis, bicarbonate treatment for acidosis, excessive
volume replacement in the first 4 hours and insulin
administration in the first hour of fluid replacement
[12]. However, some studies suggested that cerebral
edema occurs most frequently and with greatest severity
in children with greater dehydration and hypocapnia
[23,39-41]. In a recent review, Glaser pointed to the
possible involvement of cerebral ischemia and reperfu-
sion injury in causing DKA-related cerebral edema and
cerebral injury, suggesting a need to re-examine DKA
treatment protocols to determine whether injury could
be lessened by optimizing rehydration strategies [42].
Cerebral edema diagnosis is clinical and the presence of
the following symptoms shall alert to its occurrence:
headache and slowing of heart rate, change in neurologic
status (irritability, increased drowsiness, urine inconti-
nence), specific neurological signs such as cranial nerve
palsies, decerebration or decortication posture [12]. In
case of clinical suspicion, treatment must be started
quickly by administering mannitol 0.5-1 g/kg IV, in 20
minutes, which may be repeated if there is no response
within 30 minutes and 2 hours; fluid infusion must be
reduced by 1/3, and the head of the bed should be ele-
vated. In case of suspicion of herniation, the patient must
also be intubated in order to maintain hyperventilation
(pCO2 between 27-30 mmHg); however, aggressive
hyperventilation, with pCO2 < 22 mmHg, must be
avoided because it has been associated with poor out-
come [12,14]. After the treatment is initiated, a cranial
tomography will be conducted in order to exclude cere-
bral thrombosis or hemorrhage [12].
Since this alternative DKA management protocol was
adopted in our emergency department in 1996, approxi-
mately 30 DKA episodes per year have been treated, and
neither cerebral edema nor related deaths were reported
in this period [30]. The use of elevated volumes of saline
solution (0.9% sodium chloride) could be associated with
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Page 6 of 9Table 3 Biochemical characteristics (Mean ± SD) of DKA episodes treated with subcutaneous rapid-acting insulin analog (SC Analog; n = 30) and continuous intravenous regular
insulin (IV Insulin; n = 30) during the first 30 hours of management with the same alternative fluid replacement therapy
Time Insulin
Therapy
Blood Glucose
(mg/dl)
pH HCO
-
3
(mmol/L)
b-OH butyrate
(mmol/L)
Na
+ (mEq/L) Cl(mEq/L) K
+ (mEq/L) Phosphorus
(mg/dl)
Urea
(mg/dl)
Serum Osmolality
(mOsm/kg)
Admission IV Insulin 442.7 ± 146.2 7.18 ± 0.1 9.08 ± 3.61 8.45 ± 2.75 136.7 ± 4.1 105.1 ± 9.4 5.1 ± 0.8 5.1 ± 1.6 37.8 ± 15.4 312.9 ± 13.8
SC Analog 443.7 ± 143.2 7.17 ± 0.1 10.38 ± 4.74 8.16 ± 3.53 137.1 ± 4.8 109.9 ± 6.6 5.1 ± 0.6 5.0 ± 1.3 37.5 ± 10.1 311.9 ± 13.7
Hour 2 IV Insulin 332.9 ± 74.6 7.19 ± 0.11 9.76 ± 4.08 7.08 ± 2.56 139.8 ± 4.5 108.3 ± 9.9 4.8 ± 0.8 3.9 ± 1.0 34.1 ± 14.3 310.9 ± 12.4
SC Analog 335.7 ± 126.8 7.15 ± 0.13 9.83 ± 5.71 7.54 ± 3.53 139.0 ± 5.6 107.9 ± 8.4 5.0 ± 0.9 4.3 ± 1.1 32.5 ± 10.0 305.8 ± 16.2
Hour 6 IV Insulin 222.6 ± 42.1 7.24 ± 0.12 9.76 ± 4.08 4.08 ± 2.58 140.1 ± 5.4 109.8 ± 9.3 4.4 ± 0.9 3.3 ± 1.2 30.7 ± 13.0 305.4 ± 13.7
SC Analog 213.6 ± 66.8 7.22 ± 0.12 9.83 ± 5.71 5.18 ± 3.17 140.4 ± 5.4 112.4 ± 9.9 4.6 ± 0.8 3.3 ± 0.9 28.6 ± 8.6 302.2 ± 13.3
Hour 12 IV Insulin 187.7 ± 86.3 7.31 ± 0.09 15.79 ± 4.42 2.61 ± 2.18 139.1 ± 4.0 110.2 ± 6.9 4.1 ± 0.6 2.8 ± 0.8 24.8 ± 12.9 297.6 ± 11.2
SC Analog 241.4 ± 82.7 7.29 ± 0.08 14.25 ± 6.10 3.29 ± 2.84 137.5 ± 3.9 108.3 ± 6.9 4.1 ± 0.5 3.0 ± 1.0 27.0 ± 7.3 296.5 ± 10.34
Hour 18 IV Insulin 241.9 ± 122.0 7.36 ± 0.04 18.39 ± 3.66 1.57 ± 1.82 137.8 ± 4.0 104.8 ± 8.1 3.9 ± 0.4 2.6 ± 0.8 26.9 ± 12.0 297.6 ± 11.2
SC Analog 210.6 ± 100.7 7.31 ± 0.05 16.78 ± 6.27 2.0 ± 2.0 138.1 ± 2.8 109.0 ± 6.3 3.8 ± 0.5 3.0 ± 1.0 27.2 ± 8.0 296.5 ± 10.3
Hour 30 IV Insulin 269.7 ± 133.5 7.37 ± 0.07 19.52 ± 5.10 0.84 ± 0.91 138.3 ± 5.2 106.9 ± 6.8 3.7 ± 0.5 2.5 ± 1.1 26.2 ± 10.8 302.4 ± 10.1
SC Analog 245.9 ± 91.1 7.37 ± 0.06 18.19 ± 4.72 1.12 ± 1.59 137.2 ± 3.0 106.8 ± 7.9 4.0 ± 0.4 2.5 ± 0.8 26.5 ± 8.3 297.2 ± 5.4
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9development of hyperchloremic acidosis [43], however
such complication has not been demonstrated during the
30 hours of treatment (Table 3). On the other hand, a
positive tendency of natremia during rehydration has
been associated with a favorable outcome and less inci-
dence of brain edema [39,44].
An important point of care in DKA treatment is pre-
venting its recurrence, since all of its causes are preven-
table. Insulin omission or difficulties to deal with
stressful events of life are the most common causes.
Therefore, patients and family members must be edu-
cated and undergo training for intensive monitoring,
ketone detection and insulin dose adjustments during
intercurrent illness periods. Adult supervision of insulin
administration, psychological assessment and support
for patients and their family may contribute to the
reduction in frequency of recurrent DKA [8,12].
Conclusion
We presented here a local experience with an alternative
protocol designed to abbreviate the time on intravenous
infusion lines in order to facilitate DKA management in
general emergency wards. The main differences between
this protocol and the international guidelines are: intrave-
nous fluid will be stopped in the moment when oral fluid
is well tolerated and total deficit will be replaced orally; if
electrolyte measurements still indicate need for replace-
ment, it will be given orally; SC rapid-acting insulin analog
is administered at 0.15 U/kg dose every 2-3 hours until
resolution of metabolic acidosis; approximately 12 hours
after treatment beginning, intermediate-acting (NPH)
insulin is initiated at the dose of 0.6-1.0 U/kg/day, and this
dose will be lowered to 0.4-0.7 U/kg/day at discharge from
hospital. Since 1996, when this alternative DKA manage-
ment protocol was adopted in our emergency department,
neither cerebral edema nor related deaths were reported.
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